Rep. Ken Calvert

Maddy summaryThis bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.

Maddy summaryThis bill, titled the National Security Interstate Pipeline Act, allows the President to designate specific oil and natural gas pipelines as critical to national security, thereby placing them under exclusive federal control for siting and permitting. Once designated, the Federal Energy Regulatory Commission becomes the sole lead agency responsible for approving these projects, bypassing state and local regulations that could delay construction. The legislation also grants pipeline companies the right to use eminent domain to acquire necessary land after a good-faith negotiation attempt and permits the President to waive certain environmental laws if delays threaten national defense. Additionally, the bill sets strict timelines for federal and state agencies to complete reviews, deeming requirements satisfied if actions are not taken within specified periods, while requiring the President to report these designations and waivers to Congress.

Maddy summaryThe Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.

Maddy summaryHR 4283 designates the U.S. Postal Service facility at 1157 West Mission Avenue in Escondido, California, as the "Captain E. Royce Williams Post Office Building." The bill updates all official references (laws, maps, documents) to this specific post office to use the new name. This is a ceremonial naming bill with no policy changes or direct impact on citizens' rights or obligations. It affects only the postal facility's official designation and related records.

Maddy summaryThis bill, known as the STOP Nitazenes Act, directs the federal government to permanently classify nitazenes and related synthetic opioids as Schedule I controlled substances, placing them in the same legal category as heroin and fentanyl. The legislation specifically targets a broad range of chemical compounds, including etonitazene and other variants, by defining them as 2-benzylbenzimidazole opioids and requiring the Attorney General to publish a list of qualifying substances. Under the bill, any nitazene substance temporarily scheduled under emergency provisions would be made permanently scheduled upon enactment, ensuring long-term federal control. The law also mandates that the Attorney General issue implementing rules within one year, allowing for immediate interim enforcement while providing opportunities for public comment before final regulations are established.

Maddy summaryHR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryHR 4288 would rename the Department of Veterans Affairs community-based outpatient clinic in San Jose, California, as the "Corporal Patrick D. Tillman VA Clinic." The bill directly affects this specific VA facility, updating all official references to it. The key provision requires the clinic to be designated by this new name in all federal records, documents, and maps following the bill's enactment. This is a procedural naming bill honoring Corporal Tillman, a former NFL player and Army Ranger killed in action in Afghanistan in 2004.

Maddy summaryHR 7651, the Chloe Cole Act of 2026, prohibits healthcare providers from performing certain medical interventions on minors under 18 aimed at altering physical development to align with gender identity. These "covered interventions" include puberty blockers, hormone treatments, and specific surgeries, but exclude medically necessary care for conditions like disorders of sexual development or traumatic injuries. The bill creates a federal civil lawsuit right for affected minors or their parents against providers who perform such interventions, allowing claims for damages including emotional distress and punitive awards, with strict liability for providers after the law's enactment. It explicitly allows exceptions for legitimate medical treatments and requires providers to prove such exceptions apply if challenged.

Maddy summaryThis bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.